ANN ARBOR, Mich., Sept. 17 (UPI) -- U.S. scientists are starting a phase-1 clinical trial that involves using gene therapy to treat cancer-related intractable pain.
The University of Michigan study uses a genetic transfer vector injected into the skin to deliver a pain-relieving gene to the nervous system. The investigators will use a vector created from herpes simplex virus -- the virus that causes cold sores -- to deliver the gene for enkephalin, one of the body's own natural pain relievers.
"After almost two decades of development and more than eight years of studies in animal models of pain, we have reached the point where we are ready to find out whether this approach will be effective in treating patients," said Dr. David Fink, a professor of neurology. Fink developed the vector with collaborators and will direct the study.
Fink said the trial represents two firsts: It is the first human trial of gene therapy for pain, and the first study to test a non-replicating HSV-based vector to deliver a therapeutic gene to humans.
If successful, Fink says the technique may hold promise for treating other types of chronic pain. But, he cautioned, a treatment is at least several years away.
